Project Grant R01CA293755
Award Date 8/13/25
Completion Date 4/30/30
Dollars Obligated $549K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research aimed at understanding how different forms of cell death, particularly programmed necrosis, can alter the immune response and impact tumor growth. The $568,538 award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. will fund a 5-year study to investigate the role of the cytokine interleukin-1 alpha in mediating immune suppression and promoting...
- This $697,590 federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to evaluate B-T cell cross-talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The grant, with a performance period from July 1, 2024 to June 30, 2027, aims to advance scientific understanding of...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $328,575 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. This 3-year grant, with a start date of September 1, 2024, will support research aimed at "Reversing Exhaustion of Tumor-Infiltrating Lymphocytes for Improvement of Adoptive Cell Therapy." As a National Cancer Institute-designated comprehensive cancer...
- This federal Project Grant award of $123,182 was provided by the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant supports research to investigate the mechanisms of dormant breast cancer cells and their interactions with the surrounding environment. The key objectives are to determine how the HIRA/H3.3 chromatin regulation axis controls dormant cancer...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This $549,962 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) aims to determine how antibodies and cellular ligands regulate the immunosuppressive function of Lymphocyte-Activation Gene 3 (LAG3). The research will explore the molecular mechanisms by which LAG3 engages with Major Histocompatibility Complex Type II (MHCII) and Fibrinogen-Like 1 (FGL1) ligands to control T cell activation. The findings are expected to inform the...
- The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $219,491 to the Mayo Clinic Jacksonville to conduct research on the epigenetic regulation of T cell metabolism and immune functions by the SIRT6 protein. The research aims to understand how SIRT6 impacts the metabolic activity and effector functions of tumor-reactive T cells, with the goal of identifying ways to boost T cell metabolism and enhance cancer immunotherapies. The study will...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $734,942 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project, titled "Aging, DNA Methylation, and Incident Cardiovascular Disease in Breast Cancer Survivors," aims to generate new blood DNA methylation data and conduct research to better...
- This federal Project Grant award of $663,340 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to elucidate the mechanisms by which the ablation of intratumoral regulatory T cells can mobilize NK cells and CD4 T cells to control MHC I-deficient tumors. The research aims to determine how CD4 T cell help enhances the antitumor function of NK cells, including the role of cytokines like IL-2 and IL-15, as well as test whether intratumoral Treg depletion...